Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230
May 25, 2016 at 11:47 AM EDT
Alkermes Plc (NASDAQ: ALKS) revealed Wednesday that it initiated a phase 1 clinical trial of its immuno-oncology drug candidate, ALKS ...
